|
|
 |
|
Viewing report
|
|
|
|
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Bioseeker, April 2011, Pages: 1,147
This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. BioSeeker has applied its unique drug assessment methodology to stratify the leukemia pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of leukemia drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing leukemia drugs in 41 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the leukemia drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, TOP2A, MS4A1 and CD33.
- Eight out of ten drug target strategies in Phase II development are new to leukemia drugs and at the same time the greatest numbers of new target strategies are found in Phase II (34%) and Phase I development (19%).
- Small molecules, antibodies and proteins are the dominating compound strategies of leukemia drugs, which represent almost 90% of the entire pipeline. Cell therapy based leukemia drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of leukemia drugs.
- The highest number of described drug target strategies of leukemia drugs belongs to Novartis (9), Pfizer (9) and Bristol-Myers Squibb (8).
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any leukemia drug to ensure that the optimal market conditions exist by the time the product is commercialized.
|
|
|
|
